BioAtla, Inc. (BCAB)
Fuera de horario:
BioAtla, Inc.
11085 Torreyana Road
San Diego, CA 92121
United States
858 558 0708
https://www.bioatla.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 65
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jay M. Short Ph.D. | Co-Founder, CEO & Chairman | 1.13M | N/D | 1958 |
| Mr. Richard A. Waldron | Senior VP & CFO | 655.94k | N/D | 1954 |
| Dr. Eric L. Sievers M.D. | Chief Medical Officer | 654.59k | N/D | 1964 |
| Mr. Christian J. Vasquez | Chief Accounting Officer, Controller and Corporate Secretary | 408.75k | N/D | 1976 |
| Ms. Susie Melody | Senior Vice President of Human Resources | N/D | N/D | N/D |
| Dr. Cathy Chang Ph.D. | Senior Vice President of Research & Development | N/D | N/D | N/D |
| Dr. Gerhard Frey Ph.D. | Senior Vice President of Technology Development | N/D | N/D | N/D |
| Ms. Monica Sullivan | Senior Vice President of Intellectual Property & Contracts | N/D | N/D | N/D |
| Ms. Sheri Lydick | Chief Commercial Officer | N/D | N/D | N/D |
| Dr. Bin Zhang | Senior Vice President of Clinical Development | N/D | N/D | N/D |
Descripción
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Gestión corporativa
La calificación ISS Governance QuickScore de BioAtla, Inc. a partir del 1 de junio de 2024 es 8. Las puntuaciones principales son Auditoría: 5; Junta: 8; Derechos del accionista: 8; Compensación: 8.
